Do all gliflozins reduce stroke in patients with type 2 diabetes mellitus and impaired renal function?
We have read with great interest a study of meta-analysis1 recently published in Journal of Stroke and Cerebrovascular Diseases. In that study1 Barkas and colleagues drew their main conclusion that sodium-glucose transporter 2 (SGLT2) inhibitors reduce the risk of total stroke in patients with type 2 diabetes mellitus (T2DM) and impaired renal function (IRF), which was based on the result of meta-analysis on the outcome of total stroke (including ischemic and hemorrhagic stroke) in the subgroup of patients with T2DM and IRF (Fig.
Source: Journal of Stroke and Cerebrovascular Diseases - Category: Neurology Authors: Li-Min Zhao, Liang-Liang Ding, Ze-Lin Zhan, Mei Qiu Tags: Letter to the Editor Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Hemorrhagic Stroke | Ischemic Stroke | Neurology | SGLT2 Inhibitors | Sodium | Stroke | Study